SCHEMBL5409399

SCHEMBL5409399

COc1cccc(CCN(CCC(=O)O)C(=O)c2ccccc2-c2ccccc2C(=O)NCc2ccco2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.54
NPSR1 Q6W5P4 1/20 0.48
TDP1 Q9NUW8 3/20 0.48
TSHR P16473 3/20 0.47
TP53 P04637 2/20 0.47
POLB P06746 2/20 0.47
SGMS2 Q8NHU3 1/20 0.45
ALDH1A1 P00352 7/20 0.45
HPGD P15428 4/20 0.45
KDM4E B2RXH2 3/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
NPC1 O15118 2/20 0.45
HTT P42858 2/20 0.45
HSD17B10 Q99714 2/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
USP2 O75604 1/20 0.44
GAA P10253 1/20 0.44
MAPK1 P28482 1/20 0.44
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5399044 0.93 NPSR1 (0.50) RAB9ANPSR1TDP1TSHRTP53
SCHEMBL5414358 0.92 HPGD (0.49) RAB9ANPSR1TSHRTP53POLB
SCHEMBL5402213 0.91 ALDH1A1 (0.55) RAB9ANPSR1TDP1TSHRTP53
SCHEMBL5394900 0.90 RAB9A (0.64) RAB9ATP53POLBALDH1A1HPGD
SCHEMBL5398996 0.90 RAB9A (0.67) RAB9ATP53POLBALDH1A1HPGD
SCHEMBL5403781 0.88 ALDH1A1 (0.52) NPSR1TDP1TSHRTP53POLB
SCHEMBL5399552 0.88 RAB9A (0.67) RAB9ATP53POLBALDH1A1HPGD
SCHEMBL5408664 0.88 RAB9A (0.53) RAB9ANPSR1TSHRPOLBALDH1A1
SCHEMBL5397871 0.87 RAB9A (0.61) RAB9ATP53POLBALDH1A1HPGD
SCHEMBL5392884 0.87 TDP1 (0.53) RAB9ANPSR1TDP1TSHRTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7285680-B2 β-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-10-23 US disclosed
US-20050256160-A1 Beta-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2005-11-17 US disclosed
EP-1533294-A1 BETA-ALANINE DERIVATIVE AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256160-A1 Beta-alanine derivatives and the use thereof TGFB1, PML, APOB RAB9A 3132/4885NPSR1 171/4885TDP1 1939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.